166 related articles for article (PubMed ID: 35294478)
1. CHST4 might promote the malignancy of cholangiocarcinoma.
Zhang G; Liu X; Jian A; Zheng K; Wang H; Hao J; Zhi S; Zhang X
PLoS One; 2022; 17(3):e0265069. PubMed ID: 35294478
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of Novel Biomarkers and Potential Targeted Drugs in Cholangiocarcinoma: Bioinformatics, Virtual Screening, and Biological Evaluation.
Wang J; Zhu W; Tu J; Zheng Y
J Microbiol Biotechnol; 2022 Oct; 32(10):1262-1274. PubMed ID: 36224755
[TBL] [Abstract][Full Text] [Related]
3. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
6. A2M is a potential core gene in intrahepatic cholangiocarcinoma.
Zhang G; Liu X; Sun Z; Feng X; Wang H; Hao J; Zhang X
BMC Cancer; 2022 Jan; 22(1):5. PubMed ID: 34979994
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma.
Li H; Long J; Xie F; Kang K; Shi Y; Xu W; Wu X; Lin J; Xu H; Du S; Xu Y; Zhao H; Zheng Y; Gu J
Oncol Rep; 2019 Nov; 42(5):1833-1842. PubMed ID: 31545466
[TBL] [Abstract][Full Text] [Related]
8. Identification of hub genes and pathways in cholangiocarcinoma by coexpression analysis.
Kong J; Shen S; Zhang Z; Wang W
Cancer Biomark; 2020; 27(4):505-517. PubMed ID: 32116234
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data.
Zhong W; Dai L; Liu J; Zhou S
Mol Med Rep; 2018 Apr; 17(4):5744-5753. PubMed ID: 29436659
[TBL] [Abstract][Full Text] [Related]
10. RNA-sequencing reveals the expression profiles of tsRNAs and their potential carcinogenic role in cholangiocarcinoma.
Li YK; Yan LR; Wang A; Jiang LY; Xu Q; Wang BG
J Clin Lab Anal; 2022 Oct; 36(10):e24694. PubMed ID: 36098712
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatic analysis the expression and clinical significance of CDRT15 in cholangiocarcinoma using TCGA database.
Yu T; Zhang T; Zhao L; Li K; Li J; Yu A
Medicine (Baltimore); 2023 Aug; 102(31):e34602. PubMed ID: 37543771
[TBL] [Abstract][Full Text] [Related]
12. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.
Huang QX; Cui JY; Ma H; Jia XM; Huang FL; Jiang LX
Cancer Gene Ther; 2016; 23(2-3):48-53. PubMed ID: 26679756
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.
Qin X; Song Y
Med Sci Monit; 2020 May; 26():e921815. PubMed ID: 32435051
[TBL] [Abstract][Full Text] [Related]
14. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis.
Ren H; Luo M; Chen J; Zhou Y; Li X; Zhan Y; Shen D; Chen B
Oncol Rep; 2019 Dec; 42(6):2622-2634. PubMed ID: 31661142
[TBL] [Abstract][Full Text] [Related]
15. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
16. cDNA microarray profiling of rat cholangiocarcinoma induced by thioacetamide.
Yeh CN; Weng WH; Lenka G; Tsao LC; Chiang KC; Pang ST; Chen TW; Jan YY; Chen MF
Mol Med Rep; 2013 Aug; 8(2):350-60. PubMed ID: 23754683
[TBL] [Abstract][Full Text] [Related]
17. [Screening core genes and cyclin B2 as a potential diagnosis, treatment and prognostic biomarker of hepatocellular carcinoma based on bioinformatics analysis].
Yang SY; Ren H; Li CF; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2020 Sep; 28(9):773-783. PubMed ID: 33053978
[No Abstract] [Full Text] [Related]
18. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
Qiu G; Ma D; Li F; Sun D; Zeng Z
Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide identification of a competing endogenous RNA network in cholangiocarcinoma.
Li G; Liu T; Zhang B; Chen W; Ding Z
J Cell Biochem; 2019 Nov; 120(11):18995-19003. PubMed ID: 31270845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]